Compare Eaton Corporation plc (ETN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs BIO-TECHNE Corp — how do they compare? Eaton Corporation plc trades at $459.14 (market cap $172.82B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Eaton Corporation plc is far larger — about 15.4× BIO-TECHNE Corp's market cap, and Eaton Corporation plc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| ETN | TECH | |
|---|---|---|
Market Cap | $172.82B | $11.24B |
Sector | Technology | Health |
52-Week High | $448.68 | $72.29 |
52-Week Low | $315.82 | $43.31 |
Enterprise Value | $193.45B | $11.32B |
Dividend Yield | 0.99% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $448.68, up 0.11% on the day and near its 52-week high, supported by a bullish technical trend and strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 exceeding the $3.07 estimate, and raised its full-year outlook. Revenue growth is robust, driven by surging demand in electrical and aerospace segments, particularly from data center expansion.
The outlook remains positive given raised guidance and analyst consensus, but the stock's premium valuation (P/E of 45.31) poses a risk if growth moderates. Key opportunities include exposure to AI-driven power infrastructure spending, while risks involve execution challenges and macroeconomic sensitivity. The consensus price target of $496.50 implies ~11% upside from current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
